-
Cy5 hydrazide for Carbonyl Labeling
2026-09-17
Cy5 hydrazide enables sensitive carbonyl-selective fluorescence for oxidized proteins, periodate-activated glycoproteins, aldehyde-bearing oligonucleotides, and nanoparticle interface studies. This guide combines practical labeling conditions with controls that separate covalent biomolecule labeling from nonspecific particle association.
-
Sulfaphenazole: CYP2C9 Inhibitor Workflows
2026-09-17
Sulfaphenazole is a practical CYP2C9 inhibitor for connecting drug-metabolism experiments with vascular, oxidative-stress, wound-healing, and antibacterial models. This workflow-focused guide covers solvent handling, assay design, translational readouts, and troubleshooting for reproducible use.
-
Clarithromycin: A Strategic CYP3A DDI Tool
2026-09-16
A translational framework for using Clarithromycin as a mechanistically defined CYP3A inhibitor in drug-drug interaction research, pharmacokinetic studies, statin metabolism interaction programs, and cardiovascular development.
-
Clathrin-Mediated Entry of Type III GCRV
2026-09-16
Wang et al. combined inhibitor profiling, transmission electron microscopy, and quantitative PCR to show that genotype III grass carp reovirus enters CIK cells through a dynamin-dependent, acidification-sensitive clathrin pathway. IPA-3 did not measurably inhibit infection in this model, providing a useful negative pharmacological comparator rather than evidence that Pak1 drives viral entry.
-
Dihydroethidium (DHE) Workflow for Superoxide
2026-09-15
Build a reproducible live-cell oxidative stress assay with Dihydroethidium (DHE), from DMSO stock preparation through quantitative red-fluorescence analysis. The workflow connects intracellular superoxide measurement with ferroptosis, apoptosis research, acute lung injury, and cardiovascular disease research while clarifying the probe’s specificity limits.
-
Phosbind Acrylamide for Protein Phosphorylation
2026-09-15
Phosbind Acrylamide converts phosphorylation into an interpretable SDS-PAGE mobility difference, reducing dependence on phospho-specific antibodies. This practical workflow applies the reagent to DNA-PKcs–TAF7–mTORC1 questions in kidney fibrosis while emphasizing controls, gel design, and troubleshooting.
-
MDM1, p53, and Chemoradiotherapy Sensitivity in CRC
2026-09-14
The reference study identifies MDM1 as a mechanistic determinant and potential biomarker of chemoradiotherapy response in colorectal cancer. Its experiments connect MDM1 overexpression with reduced YBX1 occupancy at the TP53 promoter, increased p53 expression, apoptosis, and greater treatment sensitivity.
-
HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus
2026-09-14
The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus supports in vitro transcription of randomly Cy3-modified RNA probes for fluorescence-based workflows. It is intended for research applications such as in situ hybridization and Northern blotting, not for diagnostic, therapeutic, or clinical use.
-
PA-824: Mechanism and Tuberculosis Research Use
2026-09-13
PA-824 is a bicyclic nitroimidazole derivative and tuberculosis research compound with activity against replicating and non-replicating Mycobacterium tuberculosis. Its nitro-reduction biology, inhibition of ketomycolate biosynthesis, and reported respiratory effects support its use as a mechanistic Mycobacterium tuberculosis inhibitor, while assay context and formulation controls remain essential.
-
Staurosporine Workflows for Apoptosis Research
2026-09-12
Staurosporine combines apoptosis induction with broad kinase-pathway perturbation, making it useful for cancer research, receptor signaling, and angiogenesis assays. This workflow guide shows how to separate true cell-death biology from nonspecific cytotoxicity through controlled dosing, orthogonal readouts, and troubleshooting.
-
Acetylspiramycin: Applied Research Workflows
2026-09-12
Acetylspiramycin (Spiramycin B) supports side-by-side susceptibility, resistance, and host-response studies rather than a single endpoint assay. This guide connects broth microdilution, ribosome-focused experiments, and multiplex pathogen detection with practical controls for solubility, dosing, and interpretation.
-
Microlipophagy and Radioresistance in SCLC
2026-09-11
A 2026 study links microlipophagy-driven lipid-droplet remodeling with radioresistant phenotypes in small-cell lung cancer. Its integrated imaging, lipid profiling, pharmacological inhibition, and transcriptomic design suggests that autophagy-dependent metabolic adaptation may be a tractable research target, while also highlighting important limits to causal interpretation.
-
In Vitro Drug Response Metrics in Cancer
2026-09-11
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-equivalent dimensions of anticancer response. Its central practical implication is that drug screens should separate proliferative arrest from death and account for their different timing rather than treating one viability value as a complete response profile.
-
Griseofulvin Workflows for Microtubule Assays
2026-09-10
Griseofulvin provides a practical perturbation tool for connecting microtubule disruption with fungal cell mitosis inhibition. This guide combines DMSO handling, time-resolved phenotyping, flow-cytometric mechanism tests, and troubleshooting strategies for reproducible antifungal drug research.
-
Sulfaphenazole: CYP2C9 Inhibitor Workflows
2026-09-10
Sulfaphenazole is a practical probe for CYP2C9-mediated drug metabolism modulation, oxidative stress, and vascular recovery studies. This workflow-focused guide connects enzyme inhibition assays with preclinical perfusion, wound-healing, and antibacterial applications while separating established evidence from experimental starting conditions.